Search filters

List of works by Peter Buggisch

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

scientific article

Bioavailability of oral iron drugs as judged by a 59Fe-whole-body counting technique in patients with iron deficiency anaemia. Therapeutic efficacy of iron(II)-glycine sulfate

scientific article published in January 2005

Clinical management of drug-drug interactions in HCV therapy: challenges and solutions

scientific article

Current recommendations for the treatment of chronic hepatitis C

scientific article

Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial

scientific article published on 22 March 2013

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals

scientific article published on 30 August 2011

Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C?

scientific article

Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study

scientific article published on February 2006

Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases

scientific article published in December 2003

Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.

scientific article

Efficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection

scientific article published on 24 May 2015

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response

scientific article

Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

scientific article

Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection

scientific article published on 27 December 2016

Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: a randomized trial

scientific article

Evaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection

scientific article published on 23 June 2008

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

scientific article published in April 2006

Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.

scientific article published in January 2007

Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study

scientific article published on 7 February 2008

Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection

scientific article published in November 2006

Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection

scientific article published on 21 October 2011

Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders

scientific article published on 19 March 2015

Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks

scientific article published on 22 July 2011

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients

scientific article published in August 2009

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

scientific article published in January 2010

Mycophenolate mofetil as second line therapy in autoimmune hepatitis?

scientific article published on 3 October 2008

Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection

scientific article published in November 2008

Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239.

scientific article published on 08 August 2016

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy ⬇️

scientific article published on March 1, 2013

Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection

scientific article published on 26 June 2013

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

scientific article published on 13 January 2011

Sex-specific effects of TLR9 promoter variants on spontaneous clearance of HCV infection

scientific article published on 21 April 2016

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease

scientific article published on 30 January 2017

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

scientific article published on June 2017

Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection

scientific article published in August 2009

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

scientific article published in December 2008

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection

scientific article published on 13 September 2011

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

scientific article published in March 2012

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

scientific article

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

scientific article published on 16 October 2010

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

scientific article published on 18 July 2016

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

scientific article published on June 2003

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients

scientific article

“Real-Life” comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus ⬇️

scientific article published on April 1, 2011

Paulina is supported by:

About Paulina

Help